Bruce Brockstein, MD
Medical Oncology · Evanston, ILNPI 1740349695
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,710 of the $16,218 with a category attached, or 84.5%. Reporting peaked in 2023 at $9,192 and has fallen 99.7% since, to $26 in 2025.
Across 14 payments — averaging $1158.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$9K
- Merck$7K
Across 35 payments — averaging $4294.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$76K
- Regeneron$51K
- Astrazeneca UK Limited$17K
- E.r. Squibb & Sons, L.L.C.$6K
What the payments were for
- Consulting fees$13,71085%
- Speaking & faculty fees$2,10013%
- Travel & lodging$2021%
- Food & beverage$1801%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 7 | $9,100 |
| Merck | 7 | $7,118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabozantinib$4,900
- Cabometyx$4,200
How this compares
$16,218 in reported general payments places this provider in the 80th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 16 | $363,928 |
| MektoviBinimetinib | 13 | $205,412 |
| BraftoviEncorafenib | 12 | $194,409 |
| TafinlarDabrafenib Mesylate | 12 | $169,252 |
| Imatinib Mesylate | 47 | $101,241 |
| EliquisApixaban | 35 | $25,458 |
| XareltoRivaroxaban | 11 | $10,094 |
| Levothyroxine Sodium | 58 | $772 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $467 |
| Dexamethasone | 25 | $445 |
| Ondansetron Hcl | 46 | $230 |
| Prochlorperazine Maleate | 21 | $167 |
| Prednisone | 34 | $145 |
| Tramadol Hcl | 18 | $104 |
| Lorazepam | 26 | $99 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Evanston
- Poornima SahaEvanston$18K
- Daniel ShevrinEvanston$17K
- Javed ImamEvanston$4K
- Robert MarshEvanston$4K
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.